A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris

BACKGROUND: The addition of calcipotriol ointment to PUVA therapy for psoriasis vulgaris results in a lower total UVA dose and a faster onset of response. The addition of calcipotriol cream to PUVA, however, has not been studied. OBJECTIVE: To investigate whether combining calcipotriol cream with PU...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment 2004-04, Vol.15 (2), p.98-103
Main Authors: Torras, H, Aliaga, A, López-Estebaranz, JL, Hernández, I, Gardeazabal, J, Quintanilla, E, Mascaró, JM
Format: Article
Language:English
Subjects:
Administration, Cutaneous
Adult
Biological and medical sciences
Calcipotriol
Calcitriol - administration & dosage
Calcitriol - analogs & derivatives
Clinical trial
Combined Modality Therapy
Comparative study
Dermatologic Agents - administration & dosage
Double-Blind Method
Female
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Photochemotherapy
Psorias
Psoriasis - drug therapy
Psoriasis - pathology
PUVA
PUVA Therapy
Severity of Illness Index
Skin, nail, hair, dermoskeleton
Spain
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: The addition of calcipotriol ointment to PUVA therapy for psoriasis vulgaris results in a lower total UVA dose and a faster onset of response. The addition of calcipotriol cream to PUVA, however, has not been studied. OBJECTIVE: To investigate whether combining calcipotriol cream with PUVA therapy has a UVA sparing effect. METHODS: We performed a randomized, multicentre, vehicle-controlled, double-blind, 12-week comparative study including 120 patients with psoriasis covering 20-50% body surface area. The study consisted of a washout phase followed by a 10-week treatment phase. PUVA therapy three times weekly was added within 1 week after randomization. Efficacy was assessed by the Psoriasis Area and Severity Index (PASI). RESULTS: At baseline the mean PASI scores were 17.5 and 19.2 in the calcipotriol and vehicle (placebo) groups, respectively. At the end of treatment, the mean PASI scores were 2.65 and 7.03 (p90% was observed in 69% of the patients in the calcipotriol-treated group and in 36.4% of the patients in the vehicle group (p
ISSN:0954-6634
1471-1753
DOI:10.1080/09546630410023322